Page 1

CLOVIS ONCOLOGY NEWS RELEASE Clovis Oncology Announces Third Quarter 2021 Operating Results 11/3/2021 • $ 37.9M in Rubraca® ( rucaparib ) global net product revenues for Q3 2021 , up 3 % over Q2 2021 and down 2 % from Q3 2020 • Three top - line Phase 3 data read - outs for Rubraca expected in 2022 with potential to address larger ovarian and prostate cancerpatient populations in earlier lines of therapy • Phase 1 LUMIERE study of targeted radiotherapy candidate FAP - 2286 ongoing ; initial Phase 1 data expected at medical meeting in 2022 , as well as initiation of Phase 2 expansion cohorts in multiple tumor types Retired final $ 64.4M in principal amount of 2021 notes and raised net proceeds of $ 41.5M through ATM equity offering program in Q3 2021 , complementing ongoing focus on cost control • $ 171.9M in cash and cash equivalents and $ 37.5M in available funding under the ATHENA financing at September 30 , 2021 • Reduction in R & D and SG & A expense of $ 23.1M , or 23 % , and reduction in net cash used in operating activities of $ 8.3M , or 15 % , each as compared to Q3 2020 BOULDER , Colo .-- ( BUSINESS WIRE ) -- Clovis Oncology , Inc. ( NASDAQ : CLVS ) reported financial results for the quarter ended September 30 , 2021 , and provided an update on the Company's clinical development programs and regulatory and commercial outlook . " While COVID - 19 continues to impact our revenues , as fewer patients have been diagnosed and treated for ovarian cancer during the pandemic , it has not affected our development programs . We remain on track for an eventful 2022 , with three data readouts from Phase 3 ATHENA and TRITON3 studies of Rubraca with label expansion potential , as well as initial data from the ongoing Phase 1 LUMIERE study of our first targeted radiotherapy candidate FAP - 2286 anticipated during 2022 , " said Patrick J. Mahaffy , President and CEO of Clovis Oncology . " With the additional capital raised in the quarter and recent repayment of the remaining 2021 notes , we have made further progress on improving our balance sheet and remain focused on our three core strategies : expand the Rubraca label to drive revenue growth , emerge as a leader in targeted radionuclide therapy , and achieve long - term 1